ICMR Institutes: From research to impact-National Institute of Virology, Pune

Assessment of antibody kinetics in mpox cases with indigenously developed IgM and IgG ELISA

10.1002/jmv.29073 · doi-reference

Norovirus genomes detected from the Guillain-Barré syndrome (GBS) cases in a community outbreak in Pune, India, 2025

10.1016/j.jinf.2025.106604 · doi-reference

Investigations into the outbreak of chandipura virus Encephalitis, Gujarat, India, 2024

10.1002/jmv.70456 · doi-reference

Identification genetic &virological characterisation of a human case of avian influenza A(H9N2) virus from Eastern India

10.25259/ijmr_1376_2024 · doi-reference

Development of whole virion inactivated Kyasanur Forest Disease vaccine candidate and its preclinical safety and efficacy evaluation

10.3389/fimmu.2026.1786057 · doi-reference

Field evaluation of Kyasanur forest disease real-time PCR point-of-care assay

10.25259/ijmr_3018_2025 · doi-reference

Outbreak of Kyasanur forest disease (monkey fever) in Sindhudurg, Maharashtra State, India, 2016

10.1016/j.jinf.2016.03.006 · doi-reference

Phylogeography of Kyasanur forest disease virus in India (1957-2017) reveals evolution and spread in the western ghats region

10.1038/s41598-020-58242-w · doi-reference

Understanding the resurgence of chikungunya virus during 2020-2021 in Pune, India, based on genomic analyses: A seven yr study

10.1002/jmv.29253 · doi-reference

Decadal change in seroprevalence of chikungunya virus infection in Pune City, India

10.3390/v14050998 · doi-reference

An outbreak of Zika virus in western India in the metropolis of Pune in the monsoon of 2024

10.1016/j.jiph.2025.102720 · doi-reference

Zika a vector borne disease detected in newer states of India amidst the COVID-19 pandemic

10.3389/fmicb.2022.888195 · doi-reference

Rapidly deployable mobile BSL-3 laboratory: A response to the Nipah virus outbreak in Kozhikode, Kerala, India, 2023

10.1080/20477724.2025.2582036 · doi-reference

Nipah virus outbreak in Kerala state, India amidst of COVID-19 pandemic

10.3389/fpubh.2022.818545 · doi-reference

Outbreak investigation of Nipah virus disease in Kerala, India, 2018

10.1093/infdis/jiy612 · doi-reference

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG

10.4103/ijmr.ijmr_2232_20 · doi-reference

Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020

10.4103/ijmr.ijmr_3290_20 · doi-reference

Performance assessment of seven SARS-CoV-2 IgG enzyme-linked immunosorbent assays

10.1002/jmv.27251 · doi-reference

COVAXIN Study group. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial

10.1016/s0140-6736(21)02000-6 · doi-reference

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

10.1016/s1473-3099(21)00070-0 · doi-reference

SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India

10.3390/microorganisms9071542 · doi-reference

First isolation of SARS-CoV-2 from clinical samples in India

10.4103/ijmr.ijmr_1029_20 · doi-reference

Full-genome sequences of the first two SARS-CoV-2 viruses from India

10.4103/ijmr.ijmr_663_20 · doi-reference

ICMR COVID study group, COVID epidemiology data management team, COVID laboratory team, VRDLN team. Laboratory surveillance for SARS-CoV-2 in India: Performance of testing descriptive epidemiology of detected COVID-19, January 22-April 30, 2020

10.4103/ijmr.ijmr_1896_20 · doi-reference

Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India

10.4103/ijmr.ijmr_671_20 · doi-reference

Laboratory preparedness for SARS-CoV-2 testing in India: harnessing a network of Virus Research Diagnostic Laboratories

10.4103/ijmr.ijmr_594_20 · doi-reference